Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FADS1 | O60427 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941784 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HSD17B10CFTRKDM4EMAPT | |
| SCHEMBL10308375 | 0.84 | PDK2 (0.46) | ALDH1A1KDM4EMAPTGAATSHR | |
| SCHEMBL14894841 | 0.82 | MMP2 (0.60) | ALDH1A1HSD17B10CFTRKDM4EMAPT | |
| SCHEMBL9492938 | 0.80 | ALDH1A1 (0.47) | ALDH1A1HSD17B10CFTRKDM4EMAPT | |
| SCHEMBL28264379 | 0.80 | MMP2 (0.40) | ALDH1A1HSD17B10CFTRKDM4EMAPT | |
| SCHEMBL11718209 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HSD17B10CFTRKDM4EMAPT | |
| SCHEMBL11841637 | 0.80 | ALDH1A1 (0.51) | ALDH1A1HSD17B10CFTRKDM4EMAPT | |
| SCHEMBL24113861 | 0.79 | THRB (0.39) | ALDH1A1HSD17B10CFTRKDM4EMAPT | |
| SCHEMBL10137803 | 0.78 | IRAK4 (0.53) | ALDH1A1HSD17B10KDM4EMAPTGAA | |
| SCHEMBL28053752 | 0.78 | MAPT (0.50) | ALDH1A1HSD17B10CFTRKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| EP-3424926-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINS, THEIR PRODUCTION AND UTILISATION AS MEDICINE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-10-11 | — | — | US | disclosed |
| US-10023574-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180057495-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-01 | — | — | US | disclosed |
| US-20170081329-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-23 | — | — | US | disclosed |
| WO-2000066563-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0911334-A1 | QUINOLINOMORPHINANE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
| US-5691322-A | Quinoline and pyridine anchors for HMG-CoA reductase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5686433-A | CHOLESTEROL BIOSYNTHESIS INHIBITION | E.R. SQUIBB & SONS, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5506219-A | ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0444533-A2 | Quinoline and pyridine anchors for HMG-CoA reductase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0356788-A2 | Quinoline and pyridine anchors for HMG-CoA reductase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | ALDH1A1 196/4885HSD17B10 2052/4885CFTR 1398/4885 |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | ALDH1A1 4699/4885HSD17B10 4582/4885CFTR 2344/4885 |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | BRD4, BET1, BRD3 | ALDH1A1 4714/4885HSD17B10 4598/4885CFTR 2170/4885 |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | ALDH1A1 136/4885HSD17B10 3491/4885CFTR 342/4885 |
| US-20180057495-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | ALDH1A1 196/4885HSD17B10 2052/4885CFTR 1398/4885 |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | ALDH1A1 196/4885HSD17B10 2052/4885CFTR 1398/4885 |
| US-20170081329-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | ALDH1A1 196/4885HSD17B10 2052/4885CFTR 1398/4885 |
| US-10023574-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | ALDH1A1 196/4885HSD17B10 2052/4885CFTR 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.